Food and Drug Administration: Plan to Accelerate the Availability of Innovative Medicines to Patients
Al-Taj News – The Director General of the Jordan Food and Drug Administration, Rana Obeidat, confirmed that the institution is working to develop an integrated regulatory system to facilitate the availability of innovative medicines to patients, enhance the competitiveness of the pharmaceutical sector, and consolidate Jordan’s position as a regional gateway for advanced healthcare.
This came during her meeting with the Multinational Pharmaceutical Group in Jordan (MPG), headed by Rami Nassar, to discuss the latest developments in the strategic plan project aimed at attracting innovative medicines, attracting global clinical studies, and enhancing medical tourism.
Obeidat explained that the plan aims to enhance pharmaceutical security and provide modern treatments to patients, in addition to benefiting from the outcomes of implementing health technology assessment systems, foremost among them the Jordanian Patient Support Program.
She indicated that the institution intends to activate regulatory harmonization practices by the end of the current year, in parallel with studying a project to accelerate the procedures for registering innovative medicines.
For their part, the group’s representatives presented proposals to enhance cooperation between global companies and the local pharmaceutical industry, in a way that supports the availability of innovative medicines to patients and increases Jordan’s attractiveness for pharmaceutical investments and global clinical studies.
